428 related articles for article (PubMed ID: 28395363)
1. Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors.
Blaschek W
Planta Med; 2017 Aug; 83(12-13):985-993. PubMed ID: 28395363
[TBL] [Abstract][Full Text] [Related]
2. Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.
Chichger H; Cleasby ME; Srai SK; Unwin RJ; Debnam ES; Marks J
Exp Physiol; 2016 Jun; 101(6):731-42. PubMed ID: 27164183
[TBL] [Abstract][Full Text] [Related]
3. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
Girard J
Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
[TBL] [Abstract][Full Text] [Related]
4. Development of SGLT1 and SGLT2 inhibitors.
Rieg T; Vallon V
Diabetologia; 2018 Oct; 61(10):2079-2086. PubMed ID: 30132033
[TBL] [Abstract][Full Text] [Related]
5. The Na
Koepsell H
Pharmacol Ther; 2017 Feb; 170():148-165. PubMed ID: 27773781
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects.
Norton L; Shannon CE; Fourcaudot M; Hu C; Wang N; Ren W; Song J; Abdul-Ghani M; DeFronzo RA; Ren J; Jia W
Diabetes Obes Metab; 2017 Sep; 19(9):1322-1326. PubMed ID: 28477418
[TBL] [Abstract][Full Text] [Related]
7. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2.
Ghezzi C; Loo DDF; Wright EM
Diabetologia; 2018 Oct; 61(10):2087-2097. PubMed ID: 30132032
[TBL] [Abstract][Full Text] [Related]
8. Development of a cell-based nonradioactive glucose uptake assay system for SGLT1 and SGLT2.
Kanwal A; Singh SP; Grover P; Banerjee SK
Anal Biochem; 2012 Oct; 429(1):70-5. PubMed ID: 22796500
[TBL] [Abstract][Full Text] [Related]
9. Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice.
Sala-Rabanal M; Hirayama BA; Ghezzi C; Liu J; Huang SC; Kepe V; Koepsell H; Yu A; Powell DR; Thorens B; Wright EM; Barrio JR
J Physiol; 2016 Aug; 594(15):4425-38. PubMed ID: 27018980
[TBL] [Abstract][Full Text] [Related]
10. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes.
Solini A; Rossi C; Mazzanti CM; Proietti A; Koepsell H; Ferrannini E
Diabetes Obes Metab; 2017 Sep; 19(9):1289-1294. PubMed ID: 28419670
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters.
Pajor AM; Randolph KM; Kerner SA; Smith CD
J Pharmacol Exp Ther; 2008 Mar; 324(3):985-91. PubMed ID: 18063724
[TBL] [Abstract][Full Text] [Related]
13. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Lapuerta P; Zambrowicz B; Strumph P; Sands A
Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
[TBL] [Abstract][Full Text] [Related]
14. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
15. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
Vallon V; Thomson SC
Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
[TBL] [Abstract][Full Text] [Related]
16. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Gallo LA; Wright EM; Vallon V
Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
[TBL] [Abstract][Full Text] [Related]
17. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Danne T; Biester T; Kordonouri O
Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
[TBL] [Abstract][Full Text] [Related]
18. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
DeFronzo RA; Davidson JA; Del Prato S
Diabetes Obes Metab; 2012 Jan; 14(1):5-14. PubMed ID: 21955459
[TBL] [Abstract][Full Text] [Related]
19. [Contribution of the kidney to glucose homeostasis].
Segura J; Ruilope LM
Med Clin (Barc); 2013 Sep; 141 Suppl 2():26-30. PubMed ID: 24444521
[TBL] [Abstract][Full Text] [Related]
20. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
Zambrowicz B; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Boehm KA; Ruff D; Powell D; Sands A
Clin Ther; 2013 Aug; 35(8):1162-1173.e8. PubMed ID: 23911260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]